{"ok":true,"nota":{"id":"598af1ada54b38f4","slug":"un-farmaco-para-bajar-de-peso-parece-reducir-la-respuesta-del-cerebro--598af1","titulo":"Un fármaco para bajar de peso parece reducir la respuesta del cerebro a la cocaína, en ratones","resumen":"Investigadores estudiaron cómo la semaglutida, medicamento usado contra la obesidad, afecta la respuesta cerebral a la cocaína. Encontraron que aumenta la sensibilidad a la leptina en el estriado, una región ligada a la recompensa.","fuente":"biorxiv","fuenteNombre":"bioRxiv · preprints","color":"#be2628","autor":"Muldowney, J. J., Umlauf, M. C., Bocarsly, M. E.","url":"https://www.biorxiv.org/content/10.64898/2026.10.16.759697v1?rss=1","imagen":"/hoy/portada/598af1ada54b38f4","tema":"salud","subtemas":["semaglutida","adicciones","cocaina","dopamina","leptina"],"entidades":["bioRxiv"],"formato":"dato","entretenimiento":false,"pubTs":"2026-10-22T00:00:00.000Z","indexTs":"2026-10-22T22:31:26.226Z","hash":"68d7f980fde30d0390d80797e389dc1187f9502cdcc7ab007c427fd7a95a9c52","tsa":{"time":"Oct 22 22:32:10 2026 GMT","provider":"freetsa.org","sobre":"sello"},"stats":{"views":0,"likes":0,"clicks":0,"dwell":0},"tipo":"motor","registro":"hallazgo","porQueImporta":"Hay indicios de que la semaglutida, la droga detrás de varios tratamientos para bajar de peso, podría frenar el consumo de cocaína porque actúa sobre el sistema de recompensa del cerebro. Este trabajo propone un mecanismo posible, pero el experimento es preclínico y la droga entra poco al cerebro. Para alguien de acá, la pregunta de si un medicamento para la obesidad sirve también contra adicciones está abierta y no debería tomarse como tratamiento.","quienFirma":"Universidad no especificada en el resumen (preprint de bioRxiv)","confianza":"preprint","consulta":{"pregunta":"¿Un medicamento para bajar de peso debería usarse contra la adicción a la cocaína?"}},"sello":{"hash":"68d7f980fde30d0390d80797e389dc1187f9502cdcc7ab007c427fd7a95a9c52","sello":"417db47eb9c465bba4da4d68a9ac63c4ebb285eac8ea67556a4b7430e2f173ae","beacon":{"drand":{"cadena":"8990e7a9aaed2ffed73dbd7092123d6f289930540d7651336225dc172e51b2ce","ronda":6575910,"aleatorio":"ad632c470ba8c968ea920b116993e6a501688139a43318de64f5a7ea72e81de2","tiempo":"2026-10-22T22:32:00.000Z"},"nist":{"cadena":2,"pulso":1995154,"salida":"A32727015042185E787530FED53F828C26131B55C644F3F364155FFBAB02AAA2930B78FFEE6913417A86FA34480E1F05FB9B4984B59D1A0E007BB8E6E3A95F8F","tiempo":"2026-10-22T22:31:00.000Z"},"noAntes":"2026-10-22T22:32:00.000Z"},"verificacion":{"drand":true,"nist":true},"tsa":{"time":"Oct 22 22:32:10 2026 GMT","provider":"freetsa.org","sobre":"sello"},"original":{"titulo":"Semaglutide Increases Striatal Leptin Sensitivity, Impacting Dopaminergic Response to Cocaine","descripcion":"There is accumulating evidence that the GLP-1 analog, semaglutide, might effectively curb intake of cocaine via brain dopaminergic functioning, despite limited brain penetrance. However, there is currently no established mechanism elucidating how chronic semaglutide treatment regulates the dopaminergic response to cocaine. Cocaine is a highly addictive substance that produces rewarding effects primarily through antagonism of the dopamine transporter (DAT). Therapeutics for cocaine use disorder (CUD) have long targeted DAT in the hope of reducing cocaine intake. Metabolic hormones such as leptin and insulin have been shown to influence DAT, and for that reason have been explored for the regul","pubDate":"2026-10-22","url":"https://www.biorxiv.org/content/10.64898/2026.10.16.759697v1?rss=1"},"indexado":"2026-10-22T22:31:26.226Z"}}